Printed From BioPortfolio.com

Janssen submits NDA to FDA for apalutamide to treat non-metastatic castration-resistant prostate cancer

03:56 EDT 12 Oct 2017 | Pharmaceutical Business Review

Janssen Biotech has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for apalutamide, an investigational, next generation oral androgen receptor (AR) inhibitor for men with non-metastatic castration-resistant prostate cancer (CRPC).

Original Article: Janssen submits NDA to FDA for apalutamide to treat non-metastatic castration-resistant prostate cancer

More From BioPortfolio on "Janssen submits NDA to FDA for apalutamide to treat non-metastatic castration-resistant prostate cancer"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches